Understanding the Market | SKB BIO-B rose nearly 5% as the company's core product SKB264 was selected for two oral presentations at ESMO

SKB BIO-B rose nearly 5%, as of the time of writing, it rose 3.42%, reported at HKD 436, with a transaction volume of HKD 88.673 million. In terms of news, recently, SKB BIO-B announced that the company has presented multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin, Germany from October 17 to 21. CITIC Securities pointed out that the company's core product SKB264 was selected for two oral presentations at ESMO, demonstrating BIC potential in the 2L+ treatment of EGFRm NSCLC with good safety, and the indication was approved for market launch in October; the single-agent treatment for HR+/HER2- BC showed significantly better results than chemotherapy and is expected to be approved in 2026. The core product A166's clinical data was announced, showing that the single-agent treatment for HER2+ BC in the 2L+ setting surpassed T-DM1, and this indication was approved for market launch in October